Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A3 | Q92570 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3077126 | 0.92 | NR4A3 (0.51) | NR4A3SMN1; SMN2L3MBTL1POLBMAPT | |
| SCHEMBL3082725 | 0.91 | NR4A3 (0.50) | NR4A3SMN1; SMN2L3MBTL1POLBMAPT | |
| SCHEMBL1334269 | 0.84 | NR4A3 (0.62) | NR4A3SMN1; SMN2L3MBTL1POLBMAPT | |
| SCHEMBL3062669 | 0.83 | HPGD (0.56) | NR4A3SMN1; SMN2L3MBTL1POLBMAPT | |
| SCHEMBL3070766 | 0.82 | NR4A3 (0.50) | NR4A3SMN1; SMN2L3MBTL1POLBMAPT | |
| SCHEMBL3057694 | 0.80 | KEAP1 (0.56) | NR4A3SMN1; SMN2L3MBTL1POLBMAPT | |
| SCHEMBL3066180 | 0.80 | NR4A3 (0.53) | NR4A3SMN1; SMN2L3MBTL1POLBMAPT | |
| SCHEMBL3519865 | 0.79 | NR4A3 (0.59) | NR4A3SMN1; SMN2L3MBTL1POLBMAPT | |
| SCHEMBL3070631 | 0.79 | HSD11B1 (0.55) | — | |
| SCHEMBL13789663 | 0.79 | ALDH1A1 (0.72) | NR4A3SMN1; SMN2L3MBTL1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101743226-B | Inhibitors of 11beta-hydroxysteroid dehydrogenase | HOFFMANN LA ROCHE | 2012-10-10 | — | — | CN | claimed |
| CN-101743226-A | Inhibitors of 11beta-hydroxysteroid dehydrogenase | HOFFMANN LA ROCHE | 2010-06-16 | — | — | CN | claimed |
| CN-101743226-B | Inhibitors of 11beta-hydroxysteroid dehydrogenase | HOFFMANN LA ROCHE | 2012-10-10 | — | — | CN | disclosed |
| US-7790711-B2 | Inhibitors of 11β-Hydroxysteroid Dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-09-07 | — | — | US | disclosed |
| CN-101743226-A | Inhibitors of 11beta-hydroxysteroid dehydrogenase | HOFFMANN LA ROCHE | 2010-06-16 | — | — | CN | disclosed |
| US-20090023709-A1 | Inhibitors of 11B-Hyrdoxysteroid Dehydrogenase | GILLESPIE PAUL | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023709-A1 | Inhibitors of 11B-Hyrdoxysteroid Dehydrogenase | HSD17B1, HSD17B2, HSD11B1 | NR4A3 3233/4885SMN1; SMN2 2613/4885L3MBTL1 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.